Abstract Herein, we report the biological evaluation of a series of indole substituted hydrazides and hydrazines throughout the assessment of their multipotent inhibitory potency towards monoamine oxidase (MAO) A and B, semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1), and the cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Hydrazine JL72 (3-(3-hydrazinylpropyl)-1H-indole) showed a potent, reversible and non-time-dependent inhibition of MAO-A, which suggests its capacity in restoring serotoninergic neurotransmission being devoid of the side effects observed for classic MAO-A inhibitors. In addition, JL72 behaved as a moderate BuChE inhibitor. Finally, both hydrazines and hydrazides derivatives showed high affinity towards SSAO/VAP-1. Among them, JL72 behaved as a noncompetitive and the most potent inhibitor (IC 50 = 0.19 ± 0.04 lM), possessing also a significant anti-inflammatory activity. The combined inhibition of SSAO/VAP-1,
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system, associated with cognitive impairment and dementia (Goedert and Spillantini 2006) . b-Amyloid (Ab) accumulation in the brain parenchyma produces senile plaques, a characteristic hallmark of AD and also produces the vascular deposits of cerebral amyloid angiopathy (CAA) (Castro et al. 2006) . CAA is present in most cases of AD and it is characterised by the deposition of Ab in the tunica media and adventitia of leptomeningeal vessels and intracortical microvessels, thus producing the degeneration of vascular smooth muscle cells and endothelial cells (Vinters et al. 1988) . The fact that AD and cerebrovascular diseases share risk factors supports the common view that there is a link between vascular degeneration and AD. It has been suggested that the accumulation of Ab in the vessel wall causes the functional deterioration of the blood brain barrier, which is essential for the correct transport and clearance of Ab from parenchyma (Deane et al. 2004; Zlokovic 2005) .
Semicarbazide-sensitive amine oxidase, also called vascular adhesion protein-1 (SSAO/VAP-1, E.C 1.4.3.21) is a multifunctional enzyme involved in the metabolic deamination of primary amines, the functions of which depend on the tissue where it is expressed (Jalkanen and Salmi 2008) . SSAO/VAP-1 shows some overlap with monoamine oxidase [E.C.1.4.3.4] , which is responsible of the primary, secondary and tertiary amine metabolism in human brain. MAO is present in most mammalian tissues and exists as two distinct enzymatic isoforms, MAO-A and MAO-B, based on their substrate and inhibitor specificities (Johnston 1968) . SSAO/VAP-1 is a circulating and membrane-bound ectoenzyme, present in vascular tissue localised in two different types of cells such as smooth muscle cells and endothelial cells being these involved in the leukocyte and neutrophil recruitment through its SSAO catalytic activity (Koskinen et al. 2004 ). Alterations of SSAO/VAP-1 levels in human plasma have been related to several pathological situations, such as AD (Ferrer et al. 2002) and ischaemic stroke, where abnormally high plasma VAP-1/SSAO activity has been found in patients with certain vascular and/or inflammatory conditions with bad prognosis (Hernández-Guillamon et al. 2012 . In this context, the inhibition of SSAO/VAP-1 and/or MAO-A and MAO-B activities, appears as an important therapeutic target to be used in the treatment of these cerebrovascular disorders. On the other hand, low levels of acetylcholine (ACh) (Geula and Mesulam 1999) are thought to play significant roles in the pathophysiology of AD (Perry et al. 1977) . The cholinergic theory of AD suggests that the selective loss of cholinergic neurons in this disorder results in a deficit of ACh in specific brain regions that mediate learning and memory functions (Davies and Maloney 1976) . However, alterations in other neurotransmitter systems, especially the serotoninergic and dopaminergic, are also thought to be responsible for the behavioral disturbances observed in patients with AD (García-Alloza et al. 2005; Terry et al. 2008) . Thus, in addition to cholinesterase enzymes (acetylcholinesterase, AChE and butyrylcholinesterase, BuChE) and SSAO/VAP-1, monoamine oxidases also (MAO; EC 1.4.3.4) appear as an important target to be considered for the treatment of specific features of this complex and multifactorial disease.
Herein, we report the biological evaluation (MAO-A, MAO-B, SSAO/VAAP-1, AChE and BuChE inhibitory profile) of a number of indole substituted hydrazides and hydrazines. These compounds were designed and synthesized for the first time by Prof. Fernández-Á lvarez's laboratory in the IQOG (CSIC, Madrid, Spain) as potential in vitro bovine MAO inhibitors (Alemany et al. 1966 (Alemany et al. , 1975 Bernabé et al. 1971; Monge et al. 1985) . In the present work, we have found that some of them and especially JL72 (3-(3-hydrazinylpropyl)-1H-indole) are able to interact with human SSAO/VAP-1, MAO (A and B), as well as AChE and BuChE, showing an interesting pharmacological profile and suggesting their potential to be used in the therapy of cerebrovascular and cognitive decline disorders.
Materials and methods

HUVEC and HUVEC hSSAO/VAP-1 cell culture
These cell lines were prepared in our laboratory as previously described (Sole et al. 2011) . Cells were cultured in M199 (Invitrogen), supplemented with 5 % FBS, 1.2 mM L-glutamine and antibiotics (50 U/ml penicillin/ 0.05 mg/ml streptomycin). The selected antibiotic geneticin (G418) was added at a final concentration of 100 lg/ml to maintain the SSAO/VAP-1 expression in HUVEC hSSAO/ VAP-1 cells. Cells were maintained in an incubator at 37°C, 5 % CO 2 , and were subcultured every 5-7 days.
Chemistry
The indole substituted hydrazides and hydrazines JL34, JL40, JL71, JL87, JL317, JL432, JL72, JL411, and JL418 ( Fig. 1) were synthesized and purified according to the methods described in the literature (Alemany et al. 1966 (Alemany et al. , 1975 Bernabé et al. 1971; Monge et al. 1985) .
Inhibition experiments of MAO (A and B)
and SSAO/VAP-1 Mitochondria from rat liver homogenates were used as source for MAO activities (Gómez et al. 1986 ). The inhibitory activity of the compounds towards MAO-A and MAO-B was determined as previously described (Fowler and Tipton 1981), using [ 14 C]-labelled substrates (Perkin Elmer, USA). For comparative purposes, phenelzine was used as reference compound. MAO-B activity was determined towards 20 lM [ 14 C]-phenylethylamine (PEA) (2.5 mCi/mmol) and MAO-A activity towards [
14 C]-(5-hydroxy-triptamine) (5-HT) 100 lM (0.5 mCi/mmol). SSAO/VAP-1 activity was measured towards [
14 C]-benzylamine 100 lM (2 mCi/mmol) using microsomes from bovine lung as source (Lizcano et al. 1996) . Inhibition curves were made by pre-incubating the enzyme with at least nine concentrations of each compound for 30 min in 50 mM phosphate buffer (pH 7.2). A sample without compound was always present to determine the 100 % enzyme activity. The reaction was carried out at 37°C adding 25 lL of substrate in a final volume of 225 lL and stopped by the addition of 100 lL in 2 M citric acid. Radiolabelled aldehyde products were extracted into toluene/ethyl acetate (1:1, v/v) containing 0.6 % (w/v) 2,5-diphenyloxazole before liquid scintillation counting (TriCarb 2810TR). The inhibition curves were expressed in percentage of total activity and the IC 50 values were calculated by using the GraphPad Prism program (Prism 3.0, GraphPad Software Inc). Total protein was measured by the method of Bradford (1976) using bovine-serum albumin as standard. Data are the mean ± SEM of at least three different experiments realised in triplicate.
Inhibition experiments of AChE and BuChE
To assess the inhibitory activity of the compounds towards AChE (E.C.3.1.1.7) and BuChE (E.C.3.1.1.8), we followed a spectrophotometric method (Ellman et al. 1961) , using purified AChE from Electrophorus electricus (Type V-S), or BuChE from equine serum (lyophilized powder) (Sigma-Aldrich, Madrid, Spain). For comparative purposes, donepezil was used as reference compound. The reaction took place in 96-well plates in a final volume of 300 lL in 0.1 M phosphate-buffered solution (pH 8.0) containing 0.035 U/ml AChE or 0.05 U/ml BuChE and 0.35 mM of 5,5 0 -dithiobis-2-nitrobenzoic acid (DTNB, Sigma-Aldrich, Madrid, Spain). Inhibition curves were made by pre-incubating this mixture with serial dilutions of each compound for 20 min. The activity in the absence of compounds was always performed to determine the 100 % of enzyme activity. After the mentioned pre-incubation period, 0.35 mM acetyltiocholine iodide or 0.5 mM butyrylthiocholine iodide (Sigma-Aldrich) were added, allowing five more minutes of incubation, where the DTNB produces the yellow anion 5-thio-2-nitrobenzoic acid along with the enzymatic degradation of both substrates. Changes in absorbance were detected at 405 nm in a spectrophotometric plate reader (FluoStar OPTIMA, BMG Labtech). Compounds inhibiting AChE or BuChE activity would reduce the colour generation, thus, IC 50 values were calculated as the concentration of compound that produces 50 % AChE or BuChE activity inhibition. Data are expressed as mean ± SEM of at least three different experiments in triplicate.
Reversibility and time-dependence inhibition studies
To study the nature of the MAO-A enzymatic inhibition exerted by JL72, the derivative with the most interesting pharmacological profile, the activity of the enzyme was determined in the presence and in the absence of the inhibitor before and after three consecutive washings with buffer. Enzyme samples were preincubated for 30 min at 37°C with 100 nM JL72 or 40 nM clorgyline, the latter used as control of irreversible inhibition. Samples were then washed with 50 mM phosphate buffer (pH 7.2) and centrifuged at 25,000g for 10 min at 4°C consecutively three times. Finally, total protein was measured and MAO-A activity was determined as described above. We next evaluated the timedependence inhibition of the reaction. Samples of enzyme plus JL72 at the indicated concentration range (10 -9 to Fig. 1 Structures of the indole substituted hydrazides and hydrazines, and the reference compounds donepezil and phenelzine 10 -3 M), were preincubated for 0, 30, 60, 120, and 180 min before MAO-A activity determination as described above.
Kinetic analysis of MAO-A and SSAO/VAP-1 inhibition
To obtain estimates of the mechanism of action of JL72 on MAO-A and SSAO/VAP-1, reciprocal plots of 1/V versus 1/[S] were constructed at different concentration of the substrate 5-HT (10-500 lM) for MAO-A and benzylamine (10-200 lM) for SSAO/VAP-1, as previously described (Fowler and Tipton 1981) . The plots were assessed by a weighted least-squares analysis. Data analysis was performed with GraphPad Prism 3.0 software. Slopes of the reciprocal plots were then plotted against the concentration of JL72 (0-1 lM for SSAO and 50-500 lM for MAO-A) to evaluate Ki data.
Leukocyte (THP-1)-endothelial (HUVEC) cell adhesion assay HUVEC and HUVEC transfected hSSAO/VAP-1 monolayers were prepared, as previously reported (Sole et al. 2011) . For leukocyte adhesion assays, cells were pre-treated with JL72 or phenelzine at 10 lM for 1 h. Then, 1 mM methylamine (MA), a SSAO/VAP-1 specific substrate, was added to the media for the next 24 h. At the end of the treatment, calcein/AM-dyed THP-1 cells were added to the HUVEC monolayer, and were allowed to bind to the endothelial cells for 30 min at 37°C. After this period, plates were successively washed in order to discard nonbound THP-1 cells. Leukocyte-binding ability was determined by the emitted fluorescence of bound THP-1 cells, measured at ex/em 495/530 nm. Non-treated cells were used as control.
Results and discussion
MAO-A, MAO-B and SSAO enzymatic inhibition
The indole substituted hydrazines and hydrazides were first evaluated as inhibitors of MAO-A and MAO-B (from rat liver mitochondria), and SSAO (from bovine lung microsomes). Values were compared with the inhibition exerted by the reference compound phenelzine (Table 1) . Although compounds JL87, JL71, JL432, JL411, JL418 were not active for MAO-A, compounds JL40, JL34, JL317 showed a significant MAO-A inhibitory profile, acting in the micromolar range (IC 50 = 3.3 ± 0.9 to 80.3 ± 14.7 lM) (Table 1) . Interestingly, JL72 showed the highest potency (IC 50 = 0.12 ± 0.03 lM) and gave a similar value than that observed for the reference compound phenelzine (IC 50 = 0.13 ± 0.02 lM). Interestingly, we observed that only compounds JL40 and JL317 were able to interact with both MAO-A and MAO-B enzymes. Conversely, all analysed compounds showed high affinity towards SSAO/VAP-1 enzyme, showing IC 50 values ranging from 0.19 ± 0.04 lM for JL72 to 79.2 ± 10.5 lM for JL40.
From the structure-activity relationship (SAR) study some conclusions can be drawn. First of all, and comparing compounds bearing a substituent at the indole C2 position, it is clear that the N 0 -alkylidene-1H-indole-2-carbohydrazides JL87, JL71, and JL432 are very weak towards MAO-A, but moderate towards MAO-B inhibitors, while the N 0 -alkyl-1H-indole-2-carbohydrazides JL34 and JL317 are moderate and selective MAO-A inhibitors. Also note that the substitution of a methyl by a phenyl group in JL40 to render JL34 increases the inhibitory effect on MAO-A, but strongly drops its inhibitory potency on MAO-B. Comparing with compounds bearing substituents at C3 position of the indole ring, such as JL411 and JL418 the presence of the carbonyl group loses the inhibitory activity drastically in both MAO-A and MAO-B isoforms. On the other hand, JL72 is the only compound that does not have carbonyl group in its molecule. This could be the structural feature responsible for the facilitation of the interaction with the active centre showing its high inhibitory potency towards MAO-A and MAO-B comparing with the rest of molecules. It is worth to remark the high selectivity of JL72 towards MAO-A, comparing with MAO-B.
Concerning the effects on SSAO inhibition, very surprisingly, the presence of such substituents on the C2 and C3 position does not affect the inhibitory activity of these compounds. Among them, the most potent are JL34, JL411, JL418 and JL72, the more active being 3-(3-hydrazinylpropyl)-1H-indole (JL72). It is worth to remark that the presence of the indole ring in all these hydrazine analogs can induce the inhibitory interaction towards MAO-A because of the similarity towards serotonin, its specific substrate. Furthermore, they could act as potential pharmacological agents stimulating the monoaminergic and catecholaminergic transmission, showing the JL72 the highest affinity towards MAO-A inhibition. The potency of JL72 as SSAO inhibitor, suggests that this compound may also possess a good anti-inflammatory profile.
AChE and BuChE inhibition
To complete the study of the biological profile of the indole substituted hydrazides and hydrazines, the inhibitory activity against AChE (from Electrophorus electricus, EeAChE) and BuChE (from equine serum, eqBuChE) was determined by using Ellmans method (Ellman et al. 1961 ) and compared with that of the reference compound donepezil. The obtained IC 50 values are summarised in Table 1 . According to these values, the derivatives are poor inhibitors of EeAChE, with the exception of JL34 and JL72 that showed activity in the micromolar range (IC 50 = 86.4 ± 15.8 lM and 46.3 ± 2.9 lM, respectively). Nevertheless, these values are very far from the IC 50 value determined for donepezil (Table 1) , one of the most potent AChE inhibitors used in AD therapy. Similar trends were observed when the inhibitory potency was determined towards eqBuChE. In this case, only compounds JL317, JL71 and JL72 proved to be active in the micromolar range showing IC 50 from 16.1 ± 1.0 lM to 49.2 ± 11.3 lM, being the most potent 3-(3-hydrazinylpropyl)-1H-indole (JL 317), almost equipotent with donepezil. Note that, whereas compounds JL317 and JL71 are selective towards eqBuChE, JL72 is almost equipotent for both enzymes.
Concerning the SAR study, the best inhibitor for both enzymes (EeAChE and eqBuChE) is the indole hydrazine JL72, bearing the substituent at C3 position on the indole ring. Taking all these results into account, JL72 (3-(3-hydrazinylpropyl)) was selected as the most interesting compound to follow up with its biological evaluation as an indole-2-carbohydrazyde able to interact with five different enzymatic systems, all of them involved in Alzheimer's disease pathology.
Reversibility and time-dependence inhibition
To study the type of inhibition of JL72, the most potent inhibitor of the series, towards MAO-A, we analysed the reversibility/irreversibility of the binding. We observed that JL72 reversibly inhibited MAO-A, since the inhibition was significantly reverted (from 34.1 to 19.1 %) after three consecutive washings and centrifugations with buffer ( Fig. 2a) . Clorgyline was used under the same experimental conditions for comparative purposes and, in agreement with data reported in literature, behaves as an irreversible inhibitor. The reversibility of MAO-A inhibition by JL72 was also confirmed by the time-dependent inhibition analysis (Fig. 2b) , where identical inhibition was observed in spite of the different periods of incubation-time (0-180 min). The observed slight shift of the curve from zero time could be explained by the small delay in adding the substrate. This was considered not significant, since the time-independent inhibition was confirmed by finding similar inhibitory behavior at the other analysed times. Thus, these results allowed us to conclude that JL72 behaves as a reversible and non time-dependent inhibitor of MAO-A. In this regard, and because of the structural similarity with serotonin, a specific MAO-A substrate, JL72 can be considered a potent inhibitor of this MAO isoform with potential benefit in restoring and enhancing the serotoninergic transmission altered in depression and other psychological disorders.
Kinetic analysis of SSAO and MAO-A
To gain further insight into the kinetic behavior of this family of compounds on SSAO and MAO-A, a kinetic study was carried out with JL72, the most promising compound investigated. Graphical analysis of the reciprocal to Lineweaver-Burk plots (Fig. 3) , showed increased slopes (decreased V max ) and constant K m values in both enzymes analysed, indicating that JL72 behaves as a noncompetitive inhibitor and thus it binds to a different site from the active site in both MAO-A and SSAO enzymes. Replots of the slope versus concentration of JL72, gave an estimate of the inhibition constant Ki towards MAO-A of 163.2 ± 12.1 and 60.8 ± 12.5 nM towards SSAO. These results confirm the high inhibitory potency of JL72 towards both MAO-A and SSAO.
Inhibition of SSAO activity in HUVEC hSSAO/VAP-1 cells by JL72 and phenelzine
The toxicity of JL72 and phenelzine on HUVEC transfected hSSAO/VAP-1 cells was assessed as a previous step to determine their inhibitory behavior. Thus, the viability of cells treated with JL72 and phenelzine at concentration range of (0.1-100 lM) was analysed after 30-min preincubation by the MTT method (Mosmann 1983) . Phenelzine did not affect cell viability at all concentrations assayed, whereas 10 lM JL72 induced a loss of cell viability of the 20 %. Thus, the concentrations used were always lower than 10 lM. Then, in order to determine the enzymatic inhibition of hSSAO/VAP-1 expressed in HUVEC cells, treatments with JL72 and phenelzine at concentrations of 0.1, 1 and 10 lM for 30 min were carried out. SSAO/VAP-1 activity was determined in cell lysates radiometrically as previously stated in ''Materials and methods'', and expressed as percentage activity compared to non-treated cells. A complete inhibitory effect was observed at concentrations higher than 1 lM in both cases (Fig. 4) , showing that both compounds behave as potent SSAO inhibitors on HUVEC human transfected hSSAO/ VAP-1 cells model. consider whether this molecule can possess a potential antiinflammatory effect. Consequently, endothelial HUVEC wild type cells, that do not express SSAO/VAP-1, and transfected hSSAO/VAP-1 cells were cultured as described in ''Materials and methods''. When cells were treated with methylamine (MA), a specific substrate of SSAO/VAP-1, the adhesion of leukocytes significantly increased when compared with the HUVEC wild type cells. One of the functions of this multifunctional enzyme through its catalytic action is to mediate the leukocyte-adhesion in inflammatory processes (Salmi et al. 1993) . As expected, this effect disappears when transfected cells were pre-treated with JL72 or Phenelzine, confirming the antiinflammatory effect of these drugs on inhibiting the SSAO/ VAP-1 activity (Fig. 5) .
Conclusion
To sum up, some of the hydrazides and hydrazines studied here show a wide enzymatic inhibitory profile towards the two MAO isoforms, SSAO/VAP-1 and both AChE and BuChE, all them involved in Alzheimer's disease pathology. Among them, JL34, JL317, and JL72, are good and selective MAO-A inhibitors, thus possible modulators of the monoaminergic neurotransmission. In this regard, these molecules could act as potential antidepressant, and behavior enhancers, especially JL72 a highly potent and selective MAO-A inhibitor. Then, JL72, may be able to stimulate the serotoninergic, catecholaminergic and noradrenergic transmission. Some other derivatives, such as JL34, JL411, JL418, and JL72 were potent and selective inhibitors of SSAO/VAP-1. The involvement of this multifunctional enzyme in different pathologies, especially regarding Alzheimer and stroke (Ferrer et al. 2002; Hernandez-Guillamon et al. 2010 , 2012 , suggest that inhibitors of this enzyme can be a good therapeutic approach to solve these neurological disorders. Furthermore, the fact that JL72 is able to block the leukocytes adhesion in human endothelial cells, transfected with human SSAO/ VAP-1, confers to this molecule an additional antiinflammatory profile. On the other hand, JL317, JL71 and JL72 were moderate and selective BuChE inhibitors. Only the hydrazine JL72 showed a moderate non selective AChE inhibitory behavior. According to the Cholinergic hypothesis of Alzheimer's disease (Geula and Mesulam 1999) , the cholinergic transmission is affected in this disorder. The IC 50 values of JL72, herein, reported show that this compound could be able to restore cholinergic transmission by inhibiting AChE and at the same time to inhibit BuChE present in glia and both involved in Alzheimer's pathology. Recently it has been reported that the hydrazine type phenelzine, besides its antidepressant profile, it has a neuroprotective effect on neurons and astrocytes against formaldehyde-induced toxicity (Song et al. 2010 ). On the other hand phenelzine provided robust neuroprotection in the gerbil model of transient forebrain ischaemia (Wood et al. 2006) . Herein, we report a new hydrazine, JL72, that behaves as a multitarget ligand able to modulate monoaminergic transmission and besides showing an anti-inflammatory profile, both pathways known to be altered in neurological disorders. Further experimental work should be done to definitively confirm the neuroprotective effect of this novel hydrazine, JL72. The interesting pharmacological profile of JL72, together with the observation of a significant antiinflammatory activity, suggests that JL72 is a promising lead compound for further development of drugs to be used in the therapy of cerebrovascular and neurological diseases.
